Firstly, we found that pretreating cells with CPT prior to TNFα (an activator of NF-κB) stimulation significantly inhibited protein level of p65 NF-κB in the nuclear fraction of esophageal cancer cells, suggesting that CPT inhibited the activation of NF-κB pathway (Figure 5A). This evidence concerns the gene NFKB1 and esophageal cancer.